Trial Profile
Modulation of visceral fat by estrogens after menopause
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Conjugated estrogens (Primary) ; Medroxyprogesterone (Primary) ; Raloxifene (Primary)
- Indications Menopausal syndrome
- Focus Pharmacodynamics
- Acronyms AFTER
- 15 Nov 2006 Status change
- 30 Oct 2006 New trial record.
- 01 Feb 2006 Primary endpoint 'Mass-of-body-fat' has not been met.